Canopy Growth Corp. (CGC)

40.57
NYSE : Process Industries
Prev Close 40.16
Day Low/High 38.44 / 40.66
52 Wk Low/High 24.21 / 59.25
Avg Volume 4.92M
Exchange NYSE
Shares Outstanding 343.58M
Market Cap 13.93B
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer: Is This as Good as It Gets?

Jim Cramer: Is This as Good as It Gets?

Will it be too painful to stick around while you wait for the Fed to change course?

After Sears, Is J.C. Penney Next to Collapse?

After Sears, Is J.C. Penney Next to Collapse?

This is a stock with a terrible chart and questionable financials.

Canopy Growth Is Poised to Explode to the Upside

Canopy Growth Is Poised to Explode to the Upside

Let's look at the charts and technical indicators.

Play a Potential Altria Pivot Into Pot

Play a Potential Altria Pivot Into Pot

The time to scoop up Altria is now, not when some type of official announcement is made.

Canopy Growth and 4 Other Cannabis Stocks That Look Good Here

Canopy Growth and 4 Other Cannabis Stocks That Look Good Here

These stocks offer some diversification or unique features in the legal-weed space.

Chart of the Day: Constellation's Canopy Growth Engine

Chart of the Day: Constellation's Canopy Growth Engine

Canopy Growth could be Constellation's next big growth engine.

Constellation Shares Soar on Thursday

Constellation Shares Soar on Thursday

Shareholders enjoyed a crisp day of gains after Constellation cracked open a great earnings report pre-market.

Constellation Shareholders Cautious About the Company's Big Debt Burden

Constellation Shareholders Cautious About the Company's Big Debt Burden

Investors and experts need more time before they go all in on cannabis.

Analysts, Traders Bullish on Constellation as it Shatters Earnings Estimates

Analysts, Traders Bullish on Constellation as it Shatters Earnings Estimates

Market experts are abuzz over Constellation's potential new inroads into the cannabis market.

Down the Marijuana Rabbit Hole: 5 Companies to Consider

It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy.  As you go down the marijuana rabbit hole, ...

Constellation Brands Is a Bright Star on a Down Day

Constellation Brands Is a Bright Star on a Down Day

With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.

Want to Buy Constellation Brands Stock Today? Read On

Want to Buy Constellation Brands Stock Today? Read On

I have no problem blessing an investment in this name with the appropriate steps taken toward risk management.

Constellation Brands Buzzes on Raised Guidance, Growth Engines

Constellation Brands Buzzes on Raised Guidance, Growth Engines

Constellation looks to wine, beer, and cannabis to take it higher.

7 Smart Ways to Invest in Cannabis Stocks and Not Get Burned

7 Smart Ways to Invest in Cannabis Stocks and Not Get Burned

There are several avenues to invest in the potential cannabis boom -- recreational plays; medical plays; and companies that have a lot to gain from the industry but aren't reliant upon it for success.

Tilray's $400 Million Convertible Bond Private Offering

I have the honor and pleasure of book-ending your week away from Doug. On Friday, we'll get non-farm payroll and the unemployment, so I don't put much stock in the data coming this Thursday morning.  Instead, I want to start off the day talking abou...

Two Cheers for Corona and Cannabis: Constellation Jumps on Earnings

Two Cheers for Corona and Cannabis: Constellation Jumps on Earnings

Constellation looks like a star today after beating expectations.

Cannabis Shorts: Is There Enough Liquidity?

Cannabis Shorts: Is There Enough Liquidity?

Before you short cannabis names, read this.

Facebook Battles Negative Sentiment and a Weak Chart

Facebook Battles Negative Sentiment and a Weak Chart

The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.

Cannabis Could Disrupt the Lucrative Market for Painkillers

Cannabis Could Disrupt the Lucrative Market for Painkillers

Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.

Cannabis-Related Products Could Be Your Dog's Best Friend (And Your Portfolio's)

Cannabis-Related Products Could Be Your Dog's Best Friend (And Your Portfolio's)

Expert says weed-related products for pets could become a $55 billion-a-year business.

Canopy Growth CEO: Traditional Firms Will See They Must Get Into Legal Cannabis

Canopy Growth CEO: Traditional Firms Will See They Must Get Into Legal Cannabis

The only other option is 'to fearfully wait' for the legal-weed industry to expand.

Despite Taking Some Weed, Constellation Brands Charts Are Still Bearish

Despite Taking Some Weed, Constellation Brands Charts Are Still Bearish

It is entirely possible that a business relationship with Canopy Growth will help Constellation Brands, but the charts currently suggest further risk for the beverage company.

Canopy Growth Could See New Highs: Here's How to Trade This Hot Cannabis Stock

Canopy Growth Could See New Highs: Here's How to Trade This Hot Cannabis Stock

A look at CGC's charts and our latest strategy.

Canopy Growth CEO Sees Dot-Com-Like Bust for Many Weed Stocks

Canopy Growth CEO Sees Dot-Com-Like Bust for Many Weed Stocks

'There's too much hype too soon,' Canopy Growth chief Bruce Linton says.

Jim Cramer: Reefer Madness

Jim Cramer: Reefer Madness

Tilray's a disruptive company for many industries.

If You Must Trade Tilray, Use This Options Play: Market Recon

If You Must Trade Tilray, Use This Options Play: Market Recon

Covered calls may be the best bet -- or wait for a dip.

Tilray Closes up 38% After Wild Trading Day

Tilray Closes up 38% After Wild Trading Day

Shares were up 94% and down 2.3% in the same session.

Tilray and Other Cannabis Firms Have Even More Catalysts on the Horizon

Tilray and Other Cannabis Firms Have Even More Catalysts on the Horizon

Canadian marijuana legalization and U.S. approval of industrial hemp are coming.

Jim Cramer: The Tilray Short Squeeze

Jim Cramer: The Tilray Short Squeeze

Cannabis companies should be taking advantage of the mania to raise money.

Tilray's Sales Are Irrelevant and Its Charts Don't Matter

Tilray's Sales Are Irrelevant and Its Charts Don't Matter

Don't try to explain the stock's meteoric rise on a fundamental or technical basis, because it defies both.